Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

被引：0
|
作者：
Naohiro Okano
Chigusa Morizane
Shogo Nomura
Hideaki Takahashi
Hidetaka Tsumura
Hironaga Satake
Nobumasa Mizuno
Kunihiro Tsuji
Kazuhiko Shioji
Akinori Asagi
Kohichiroh Yasui
Sho Kitagawa
Tomomi Kashiwada
Atsushi Ishiguro
Masashi Kanai
Makoto Ueno
Takashi Ogura
Satoshi Shimizu
Kazutoshi Tobimatsu
Masayo Motoya
Koji Nakashima
Masafumi Ikeda
Takuji Okusaka
Junji Furuse
机构：
[1] Kyorin University Faculty of Medicine,Department of Medical Oncology
[2] National Cancer Center Hospital,Department of Hepatobiliary and Pancreatic Oncology
[3] National Cancer Center,Biostatistics Division, Center for Research Administration and Support
[4] National Cancer Center Hospital East,Department of Hepatobiliary and Pancreatic Oncology
[5] Hyogo Cancer Center,Department of Gastroenterology
[6] Kobe City Medical Center General Hospital,Department of Medical Oncology
[7] Aichi Cancer Center Hospital,Department of Gastroenterology
[8] Ishikawa Prefectural Central Hospital,Department of Gastroenterology
[9] Niigata Cancer Center Hospital,Department of Internal Medicine
[10] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[11] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology
[12] Sapporo Kosei General Hospital,Department of Gastroenterology
[13] Saga University,Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine
[14] Teine Keijinkai Hospital,Department of Medical Oncology
[15] Kyoto University,Department of Medical Oncology, Graduate School of Medicine
[16] Kanagawa Cancer Center,Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division
[17] St. Marianna University School of Medicine,Department of Clinical Oncology
[18] Saitama Cancer Center,Department of Gastroenterology
[19] Kobe University Graduate School of Medicine,Division of Gastroenterology, Department of Internal Medicine
[20] Sapporo Medical University School of Medicine,Department of Gastroenterology and Hepatology
[21] University of Miyazaki Hospital,Department of Clinical Oncology
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Pancreatic cancer; Gemcitabine; Oxaliplatin; Platinum compounds;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1835 / 1843
页数：8
相关论文
共 50 条
  • [1] Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
    Okano, Naohiro
    Morizane, Chigusa
    Nomura, Shogo
    Takahashi, Hideaki
    Tsumura, Hidetaka
    Satake, Hironaga
    Mizuno, Nobumasa
    Tsuji, Kunihiro
    Shioji, Kazuhiko
    Asagi, Akinori
    Yasui, Kohichiroh
    Kitagawa, Sho
    Kashiwada, Tomomi
    Ishiguro, Atsushi
    Kanai, Masashi
    Ueno, Makoto
    Ogura, Takashi
    Shimizu, Satoshi
    Tobimatsu, Kazutoshi
    Motoya, Masayo
    Nakashima, Koji
    Ikeda, Masafumi
    Okusaka, Takuji
    Furuse, Junji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (10) : 1835 - 1843
  • [2] Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
    Takahashi, H.
    Morizane, C.
    Nomura, S.
    Okano, N.
    Tsuda, M.
    Mizuno, N.
    Satake, H.
    Tsuji, K.
    Shioji, K.
    Ishii, H.
    Yasui, K.
    Miyakawa, H.
    Ishiguro, A.
    Ogura, T.
    Ueno, M.
    Ikeda, A.
    Terashima, T.
    Ikeda, M.
    Okusaka, T.
    Furuse, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
    Kim, G. P.
    Oberg, A. L.
    Foster, N. R.
    Jaslowski, A.
    Flynn, P. J.
    Campbell, D.
    Hedrick, E.
    Gray, L.
    Grothey, A.
    Alberts, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Guideline Concordant Genetic Testing in Patients with Breast, Ovarian, Pancreatic and Prostate Cancer
    Clark, Nina M.
    Roberts, Emma A.
    Fedorenko, Catherine
    Sun, Qin
    Dubard-Gault, Marianne
    Handford, Cynthia
    Yung, Rachel
    Cheng, Heather
    Norquist, Barbara
    Flanagan, Meghan R.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 466 - 466
  • [5] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
    Kim, George P.
    Oberg, Ann L.
    Foster, Nathan R.
    Sargent, Daniel J.
    Jaslowski, Anthony
    Campbell, Deborah
    Hedrick, Eric
    Grothey, Axel F.
    Alberts, Steve R.
    ANNALS OF ONCOLOGY, 2006, 17 : 310 - 310
  • [6] Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
    Van Cutsem, Eric
    Hidalgo, Manuel
    Canon, Jean-Luc
    Macarulla, Teresa
    Bazin, Igor
    Poddubskaya, Elena
    Manojlovic, Nebojsa
    Radenkovic, Dejan
    Verslype, Chris
    Raymond, Eric
    Cubillo, Antonio
    Schueler, Armin
    Zhao, Charles
    Hammel, Pascal
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (08) : 2053 - 2064
  • [7] First-degree family history of prostate cancer is associated the risk of breast cancer and ovarian cancer
    Zheng, QiongFei
    Ying, Qinli
    Ren, ZhengJu
    Zhang, Qin
    Lu, DongLiang
    Wang, HongBai
    Wei, WuRan
    MEDICINE, 2021, 100 (04)
  • [8] A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO
    Amanda L. Blackford
    Erica J. Childs
    Nancy Porter
    Gloria M. Petersen
    Kari G. Rabe
    Steven Gallinger
    Ayelet Borgida
    Sapna Syngal
    Michele L. Cote
    Ann G. Schwartz
    Michael G. Goggins
    Ralph H. Hruban
    Giovanni Parmigiani
    Alison P. Klein
    British Journal of Cancer, 2021, 125 : 1712 - 1717
  • [9] A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO
    Blackford, Amanda L.
    Childs, Erica J.
    Porter, Nancy
    Petersen, Gloria M.
    Rabe, Kari G.
    Gallinger, Steven
    Borgida, Ayelet
    Syngal, Sapna
    Cote, Michele L.
    Schwartz, Ann G.
    Goggins, Michael G.
    Hruban, Ralph H.
    Parmigiani, Giovanni
    Klein, Alison P.
    BRITISH JOURNAL OF CANCER, 2021, 125 (12) : 1712 - 1717
  • [10] Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
    Alberts, SR
    Townley, PM
    Goldberg, RM
    Cha, SS
    Sargent, DJ
    Moore, DF
    Krook, JE
    Pitot, HC
    Fitch, TR
    Wiesenfeld, M
    Mailliard, JA
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 580 - 585
12345